Quantitative assessment of MLAA-34 expression in diagnosis and prognosis of acute monocytic leukemia

Cancer Immunology, Immunotherapy

Volumn 60, Issue 4, 2011, Pages 587-597

  Zhao, Jianqiang ^a   He, Aili ^a   Zhang, Wanggang ^a   Meng, Xin ^a   Gu, Liufang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Acute monocytic leukemia; MLAA 34; Prognosis; Real time PCR

Indexed keywords

CYTARABINE; ETOPOSIDE; HOMOHARRINGTONINE; LEUKEMIA ANTIGEN; MITOXANTRONE; MONOCYTIC LEUKEMIA ASSOCIATED ANTIGEN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79953804874     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-0969-7     Document Type: Article

References (36)

1. Giles FJ, Keating A, Goldstone AH, Avivi I, Willman CL, Kantarjian HM (2002) Acute myeloid leukemia. Hematology 2002(1):73-110. doi:10.1182/ asheducation-2002.1.73
2. Estey E (2006) Acute myeloid leukaemia. Lancet 368(9550):1894-1907
3. Schaich M, Schlenk RF, Al-Ali HK, Dohner H, Ganser A, Heil G, Illmer T, Krahl R, Krauter J, Sauerland C, Buchner T, Ehninger G (2007) Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German acute myeloid leukemia intergroup. Haematologica 92(6):763-770. doi:10.3324/haematol.11100 (Pubitemid 350155301)
4. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom medical research council AML 10 and 12 trials. Blood 98(6):1752-1759. doi:10.1182/blood.V98.6.1752
5. Madden S, Cook D, Morris J, Gashler A, Sukhatme V, Rauscher F III (1991) Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science 253(5027):1550-1553. doi: 10.1126/science.1654597 (Pubitemid 21917311)
6. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, Suzuki A (2000) Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31(5):1080-1085 (Pubitemid 30233232)
7. Greiner J, Li L, Ringhoffer M, Barth TFE, Giannopoulos K, Guillaume P, Ritter G, Wiesneth M, Dohner H, Schmitt M (2005) Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 106(3):938-945. doi:10.1182/blood-2004-12- 4787 (Pubitemid 41076438)
8. Epping MT, Wang L, Edel MJ, Carlée L, Hernandez M, Bernards R (2005) The human tumor antigen PRAME is a dominant repressor of retinoic acid. Recept Signal 122(6):835-847 (Pubitemid 41345202)
9. Greiner J, Dohner H, Schmitt M (2006) Cancer vaccines for patients with acute myeloid leukemia - definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 91(12):1653-1661 (Pubitemid 46039635)
10. Porcu P, Cripe LD, Ng EW, Bhatia S, Danielson CM, Orazi A, McCarthy LJ (2000) Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, Clinical presentation and management. Leuk Lymphoma 39(1):1-18
11. Caligiuri MA, Schichman SA, Strout MP, Mrozek K, Baer MR, Frankel SR, Barcos M, Herzig GP, Croce CM, Bloomfield CD (1994) Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. Cancer Res 54(2):370-373 (Pubitemid 24053170)
12. PaydaŞ S, Zorludemir S, ŞAhin B (2000) Vasculitis and leukemia. Leuk Lymphoma 40(1-2):105-112. doi:10.3109/10428190009054886
13. Gang C, Wanggang Z, Xingmei C, Fuyang L, Xinping L, Libo Y (2005) Serological identification of immunogenic antigens in acute monocytic leukemia. Leuk Res 29(5):503-509
14. Zhang P-Y, Zhang W-G, He A-L, Wang J-L, Li W-B (2009) Identification and functional characterization of the novel acute monocytic leukemia associated antigen MLAA-34. Cancer Immunol Immunother 58(2):281-290
15. Anscher MS (2010) Targeting the TGF-{beta}1 pathway to prevent normal tissue injury after cancer therapy. Oncologist 15(4):350-359. doi:10.1634/theoncologist.2009-S101
16. Tamm I, Kornblau S, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero D, Tudor G, Qui Y, Monks A (2000) Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6(5):1796
17. Herr I, Debatin K-M (2001) Cellular stress response and apoptosis in cancer therapy. Blood 98(9):2603-2614. doi:10.1182/blood.V98.9.2603
18. Kawasaki H, Altieri DC, Lu C-D, Toyoda M, Tenjo T, Tanigawa N (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58(22):5071-5074 (Pubitemid 28521163)
19. Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N (2001) Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91(11):2026-2032 (Pubitemid 32476366)
20. Niu C, Yan H, Yu T, Sun H-P, Liu J-X, Li X-S, Wu W, Zhang F-Q, Chen Y, Zhou L, Li J-M, Zeng X-Y, Yang R-RO, Yuan M-M, Ren M-Y, Gu F-Y, Cao Q, Gu B-W, Su X-Y, Chen G-Q, Xiong S-M, Zhang T-d, Waxman S, Wang Z-Y, Chen Z, Hu J, Shen Z-X, Chen S-J (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94(10):3315-3324 (Pubitemid 29536124)
21. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PRK, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia group B (CALGB 8461). Blood 100(13):4325-4336. doi:10.1182/blood-2002-03-0772 (Pubitemid 35429670)
22. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta]CT method. Methods 25(4):402-408 (Pubitemid 34164012)
23. Bernstein S, Brunetto V, Davey F, Wurster-Hill D, Mayer R, Stone R, Schiffer C, Bloomfield C (1996) Acute myeloid leukemia- type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French - American - British criteria: a cancer and leukemia group B study. J Clin Oncol 14(9):2486-2494 (Pubitemid 26300115)
24. Athale UH, Razzouk BI, Raimondi SC, Tong X, Behm FG, Head DR, Srivastava DK, Rubnitz JE, Bowman L, Pui C-H, Ribeiro RC (2001) Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood 97(12):3727-3732. doi:10.1182/blood.V97.12.3727
25. San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C, Ramos F, Calmuntia MJ, Perez JJ, Gonzalez M, Orfao A (2001) Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98(6):1746-1751. doi:10.1182/blood.V98.6.1746
26. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, Sauerland MC, Berdel W, Buchner T, Hiddemann W (2003) Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML cooperative group (AMLCG) 1992 trial. Blood 101(1):64-70. doi:10.1182/blood-2002-02-0532 (Pubitemid 36025888)
27. Gajjar A, Ribeiro R, Hancock M, Rivera G, Mahmoud H, Sandlund J, Crist W, Pui C (1995) Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 86(4):1292-1295
28. Browman G, Preisler H, Raza A, Syracuse K, Azarnia N, Benger A, Chervenick P, D'Arrigo P, Doeblin T, Goldberg J, Gottlieb A, Grunwald H, Kirshner J, Larson R, Meyer R, Miller K, Priore R, Stein M, Vogler WR, Walker I, Wilson WEC, Barcos M (1989) Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study. Br J Haematol 71(4):493-497 (Pubitemid 19121331)
29. Peters WG, Willemze R, Zwaan FE, Colly LP (1988) Day-6 bone marrow aspirate for the prediction of response to remission induction therapy for acute myelogenous leukaemia. Ann Hematol 57(2):91-95
30. Liso V, Albano F, Pastore D, Carluccio P, Mele G, Lamacchia M, Mestice A, Specchia G (2000) Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia. Haematologica 85(12):1285-1290 (Pubitemid 32063699)
31. Yang YL, Li XM (2000) The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res 10(3):169-177
32. Deveraux QL, Reed JC (1999) IAP family proteins - suppressors of apoptosis. Genes Dev 13(3):239-252 (Pubitemid 29095796)
33. Nachmias B, Ashhab Y, Ben-Yehuda D (2004) The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 14(4):231-243 (Pubitemid 38824584)
34. Zhang H-G, Wang J, Yang X, Hsu H-C, Mountz JD (2004) Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23(11):2009-2015 (Pubitemid 38496730)
35. Wrzesień-Kuś A, Smolewski P, Sobczak-Pluta A, Wierzbowska A, Robak T (2004) The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Apoptosis 9(6):705-715 (Pubitemid 40941199)
36. Choi J, Hwang YK, Sung KW, Lee SH, Yoo KH, Jung HL, Koo HH, Kim H-J, Kang HJ, Shin HY, Ahn HS (2007) Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia. Blood 109(2):471-477. doi:10.1182/blood-2006-07-032557 (Pubitemid 46105940)